Predictive Oncology Inc. AIPT Cash Flow

Predictive oncology inc. (AIPT)

CashFlow / Quarterly

Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11
Net loss
-	-	-	-3,293	-	-2,506	-2,373	-1,760	-1,125	-992	-2,543	-1,341	-732	-1,055	-2,561	-2,176	-2,263	-1,116	-1,185	-225	-2,365	-1,115	-1,735	-1,616	-2,154	-3,974	-1,175	-2,101	-1,717	-2,855	-2,135	-713	-2,967	-654	-387	-477
Adjustments to reconcile net loss to net cash used in operating activities:
Loss on equity method investment
0	0	0	-439	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Depreciation and amortization
221	224	219	39	42	64	22	18	17	17	17	18	19	20	21	21	21	18	19	19	18	18	16	9	-	-	-	-	-	-	-	-	-	-	-	-
Vesting expense
246	360	1,380	263	324	339	233	226	156	10	1,544	587	18	98	10	37	551	17	230	72	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0
Issuance of common stock in cashless warrant exercise
-	-	-	-	-	-	-	-	-	-	-	-	-	67	200	468	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Depreciation and amortization
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-7	14	141	0	0	0	0	0	1	0	0	0
Equity instruments issued for management and consulting
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-3	0	-257	96	273	-91	2,413	48	1,329	166	593	9	60	1,672	265	0	0
Equity instruments issued for management and consulting
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	49	62	102	70	0	67	144	1,897	1,558	319	364	-8	65	85
Capital contributions resulting from waivers of debt
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0
Amortization of debt discount
402	552	599	468	-	-	-	-	-	-	-	-	-	-	-	-	0	0	120	98	159	87	0	0	0	321	64	28	12	0	23	21	27	28	28	27
Gain on valuation of equity-linked instruments
-137	-315	211	19	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loss on Sales of Equipment
-	-	-	-	-	-	-	-	-	-	-	-	-	0	1	-0	-0	-3	-6	-6	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Gain (loss) from sale of marketable securities
-	-	-	-	-	-	-	-	-	0	0	1	2	2	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loss (gain) on valuation of equity-linked financial instruments
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	11	3	65	69	19	-81	18	58	0	-365	23	186	4
Changes in assets and liabilities:
Accounts receivable
-75	73	-82	-59	-5	-76	73	104	45	46	-23	29	-6	21	-29	14	24	-1	-74	32	-181	88	85	-33	14	-18	5	57	-0	7	12	-31	31	18	0	0
Inventories
-30	-116	7	47	-37	33	-27	7	26	-3	-6	-23	-17	-2	35	24	-5	-20	-43	-65	51	-45	-30	269	21	-6	-33	-3	10	37	4	-5	97	0	0	0
Prepaid expense and other assets
63	33	-70	3	-69	-56	67	-81	93	8	28	11	-14	-57	50	-100	58	10	123	-110	41	-0	26	62	26	-1	-20	28	4	-43	3	32	-0	-14	39	-2
Accounts payable
-576	223	731	-13	36	243	-20	45	65	17	-21	-140	-427	-102	-41	141	-488	-1,335	10	269	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Notes payable to shareholders
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0
Accounts payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	522	40	426	32	48	-77	33	210	180	-2	31	-11	78	-26
Accrued expenses
533	856	-125	21	964	-140	-103	-226	-347	-128	-128	-265	403	-101	631	-141	-570	-2,039	647	-453	969	-165	1,002	-212	1,207	-51	-279	-100	889	38	51	59	39	28	0	24
Deferred revenue
9	0	8	-2	-	-	-	32	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred revenue
-	-	-	-	-	-	-	-	-	-3	-0	6	2	0	0	0	-24	20	-62	66	0	0	-64	0	64	0	-10	15	0	0	0	0	-	-	-	-
Net cash used in operating activities
-2,795	-1,891	-1,996	-2,048	-1,218	-962	-1,413	-1,694	-1,322	-1,066	-914	-1,156	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-136	-393	-250	-595	-378	-440	-367
Cash flow from investing activities:
Net cash used in operating activities:
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1,196	-1,587	-2,849	-4,422	-209	-5	-228	-1,195	-195	-1,752	-519	-1,213	-1,182	-940	-	-	-	-	-	-	-	-
Purchase of marketable securities
-	-	-	-	-	-	-	-	-	-	-	-	-	0	50	800	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Purchase of marketable securities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from sale of marketable securities
-	-	-	-	-	-	-	-	-	0	0	284	291	280	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Purchase of certificates of deposit
-	-	-	-	-	-	-	-	490	1	-0	2,593	100	0	0	1,000	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Redemption of certificates of deposit
-	-	-	-	0	0	0	244	1,470	1,470	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Advances on notes receivable
0	0	343	631	998	82	0	42	952	785	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Purchase of fixed assets
-	-	-	-	7	39	97	32	1	4	11	26	7	6	1	17	32	0	0	0	-1	30	0	72	112	39	9	0	0	0	0	0	0	0	0	0
Transfer of fixed assets to inventory
-	-	-	9	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Acquisition of intangibles
2	9	5	3	7	18	3	24	2	6	1	0	3	3	3	1	4	16	0	7	0	4	0	14	1	3	48	0	0	0	0	0	0	0	0	0
Net cash used in investing activities:
-	-	-	-	-	-	-	-	-	-	-	-	-	-	243	-1,818	-36	-16	0	-7	1	-35	-0	-86	-114	-43	-58	0	-	-	-	-	-	-	-	-
Net cash used in investing activities
-7	-10	43	-624	-1,014	-141	-100	145	22	672	-11	-2,336	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0
Cash flow from financing activities:
Proceeds from debt issuance
440	725	275	1,250	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Repayment of debt
544	389	126	93	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from exercise of warrants into common stock
-	-	-	-	-0	308	285	55	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from long-term and convertible debt
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	105	20	280	242	1,000	300	156	0	222	149	275	37	63	150
Repayment of convertible debt
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	100	50	0	0	0	0	0	0
Principal payments on debt
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	300	0	0	0	0	0	0	0	0	6	2	3	3
Net proceeds from issuance of preferred stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	2,055	0	0	0	0	-	-	-	-	-	-	-	-
Restricted cash in escrow
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Issuance of common stock
2,843	0	-0	2,479	0	0	0	2,959	0	0	0	3,814	1,625	0	0	86	9	13,041	0	0	0	64	0	92	126	1,205	5	1,000	258	253	184	0	394	363	85	543
Net cash provided by financing activities
2,855	1,931	897	3,635	2,184	308	285	3,015	1,300	0	0	3,814	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	203	406	149	641	398	166	689
Net decrease in cash
52	29	-1,055	962	-	-	-	1,466	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash provided by (used in) financing activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	86	9	12,127	250	0	0	1,434	105	1,867	406	1,447	1,005	1,300	-	-	-	-	-	-	-	-
Net increase (decrease) in cash
-	-	-	-	-	-	-	-	-	-	-	-	-	51	-952	-3,320	-	-	40	-12	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net increase (decrease) in cash and cash equivalents
-	-	-	-	-	-	-	-	-	-394	-926	322	-	-	-	-	-	-	-	-	-	-	-90	28	-226	191	-235	359	-88	66	12	-100	45	20	-273	321
Non-cash transactions
Bridge loan conversion into common stock
40	100	148	90	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	415	-	-	-	-	-	-	-	-
Forbearance settlement bridge loan
0	0	0	503	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Warrants Issued
0	14	23	8	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Conversion of preferred stock to common stock
-	-	-	-	0	0	0	6	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Equity method investment – Helomics
-	-	-	-	0	0	0	1,542	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Common stock issued for accrued interest/bonus
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	694	7	371	11	12	6	0	99	0	-27	0	52	0
Conversion of accounts payable to convertible debt
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	89
Common stock issued to satisfy debt
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	355	128	400	80	0	0	0	2,140	156	22	10	0	724	83	50	0	-20	20
Stock/warrant issued to satisfy accounts payable/Liabilities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	57	43	0	23	150	244	0	20	0	0	0